Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study objectives and inclusion criteria for a clinical trial on pembrolizumab for recurrent primary central nervous system lymphoma (PCNSL), while adding a new version revision and a mention of the study's location.SummaryDifference47%
Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.